Q-omics provides the consensus-scored TRIM31 profile across patient tissues and cancer cell-line models. TRIM31 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRIM31 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TRIM31 RNA expression shows 12,963 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, KICH, and ESCA as cancer lineages where TRIM31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM31 survival associations across molecular data types. TRIM31 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM31 RNA expression–survival associations across cancer types. High TRIM31 expression shows unfavorable associations in KIRP, COAD and KICH, but favorable associations in ACC, BLCA and CESC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRIM31 RNA expression.
This table summarizes TRIM31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM31 shows lower tumor expression in KICH and higher tumor expression in STAD, LUAD, LIHC, KIRC and KIRP. The KICH box plot shows higher TRIM31 RNA expression in normal versus tumor tissue (log2 FC = −0.190, t-test p < 0.001).
This table shows molecular features associated with TRIM31 in patient tissues and cancer cell lines. In patient samples, TRIM31 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
